Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/9384Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Papas, S. | en |
| dc.contributor.author | Akoumianaki, T. | en |
| dc.contributor.author | Kalogiros, C. | en |
| dc.contributor.author | Hadjiarapoglou, L. | en |
| dc.contributor.author | Theodoropoulos, P. A. | en |
| dc.contributor.author | Tsikaris, V. | en |
| dc.date.accessioned | 2015-11-24T16:48:52Z | - |
| dc.date.available | 2015-11-24T16:48:52Z | - |
| dc.identifier.issn | 1075-2617 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/9384 | - |
| dc.rights | Default Licence | - |
| dc.subject | artificial carriers | en |
| dc.subject | paclitaxel antitumor agents | en |
| dc.subject | paclitaxel derivatives | en |
| dc.subject | paclitaxel esi-ms | en |
| dc.subject | taxol derivatives | en |
| dc.subject | thioether bond | en |
| dc.subject | side-chain | en |
| dc.subject | biological-activity | en |
| dc.subject | antigenic peptides | en |
| dc.subject | hela-cells | en |
| dc.subject | taxol | en |
| dc.subject | delivery | en |
| dc.subject | proteins | en |
| dc.subject | prodrugs | en |
| dc.subject | design | en |
| dc.subject | agents | en |
| dc.title | Synthesis and antitumor activity of peptide-paclitaxel conjugates | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.primary | Doi 10.1002/Psc.899 | - |
| heal.identifier.secondary | <Go to ISI>://000250348600006 | - |
| heal.identifier.secondary | http://onlinelibrary.wiley.com/store/10.1002/psc.899/asset/899_ftp.pdf?v=1&t=h0f8qcei&s=9ee86cec45701e51c96754d8ac31ca2868641861 | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Θετικών Επιστημών. Τμήμα Χημείας | el |
| heal.publicationDate | 2007 | - |
| heal.abstract | Paclitaxel (Pac) is the most important anticancer drug used mainly in treatment of breast, lung, and ovarian cancer and is being investigated for use as a single agent for treatment of lung cancer, advanced head and neck cancers, and adenocarcinomas of the upper gastrointestinal tract. In this work, we present the synthesis of five 2'-paclitaxel-substituted analogs in which paclitaxel was covalently bound to peptides or as multiple copies to synthetic carriers. Ac-Cys(CH2CO-2'Pac)-Arg-Gly-Asp-Arg-NH2, Folyl-Cys(CH2CO-2'-Pac)-Arg-Gly-Asp-Ser-NH2, Ac-[Lys-Aib-Cys(CH2CO-2'-Pac))(2)-NH2, Ac-[Lys-Aib-Cys(CH2CO-2'-Pac)](3)-NH2 and Ac-[Lys-Aib-Cys(CH2CO-2'-Pac))(4)-NH2 were synthesized using 2'-halogeno-acetylated paclitaxel derivatives. Paclitaxel conjugates showed greater solubility in water than paclitaxel and inhibited the proliferation of human breast, prostate, and cervical cancer cell lines. Although all synthesized compounds had an antiproliferative activity, the Ac[Lys-Aib-Cys(CH2CO-2'-Pac)](4)-NH2 derivative showed improved biological activity in comparison with paclitaxel in cervical and prostate human cancer cells. Copyright (C) 2007 European Peptide Society and John Wiley & Sons, Ltd. | en |
| heal.journalName | Journal of Peptide Science | en |
| heal.journalType | peer reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά). ΧΗΜ | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| Papas-2007-Synthesis and antitu.pdf | 1.18 MB | Adobe PDF | View/Open Request a copy |
This item is licensed under a Creative Commons License
